养阴益胃健脾方联合阿帕替尼、伊立替康三线治疗晚期胃癌的疗效分析  

Analysis of effect of Yangyin Yiwei Jianpi formula combined with apatinib and irinotecan in third-line treatment of advanced gastric cancer

作　　者：张宋玲 肖威 温美如 ZHANG Songling;XIAO Wei;WEN Meiru(Department of Imaging,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Traditional Chinese Medicine,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China)

机构地区：[1]赣州市肿瘤医院影像科,江西赣州341000 [2]赣州市肿瘤医院中医科,江西赣州341000

出　　处：《癌症进展》2025年第1期25-28,共4页Oncology Progress

基　　金：江西省中医药管理局科技计划项目(2022A131)。

摘　　要：目的探讨养阴益胃健脾方联合阿帕替尼、伊立替康三线治疗晚期胃癌的疗效。方法将50例晚期胃癌患者按照随机数字表法分为对照组25例和研究组25例,对照组采取阿帕替尼+伊立替康治疗,研究组在对照组的基础上采取养阴益胃健脾方治疗。比较两组患者的临床疗效、生活质量[卡氏功能状态(KPS)评分]、中医证候积分、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)]以及不良反应发生情况。结果研究组患者疾病控制率高于对照组,不良反应总发生率低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,研究组患者KPS评分明显高于对照组,差异有统计学意义(P﹤0.01)。治疗后,两组患者各项中医证候积分均较治疗前降低,且研究组患者各项中医证候积分均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CA125、CEA水平均较治疗前降低,且研究组患者CA125、CEA水平均低于对照组,差异均有统计学意义(P﹤0.05)。结论养阴益胃健脾方联合阿帕替尼、伊立替康可明显改善晚期胃癌患者的临床疗效、中医证候及生活质量,并可降低肿瘤标志物水平,且具有一定的安全性。Objective To investigate the effect of Yangyin Yiwei Jianpi formula combined with apatinib and irinotecan in third-line treatment of advanced gastric cancer.Method A total of 50 patients with advanced gastric cancer were divided into control group(25 cases)and study group(25 cases)according to random number table method.The control group was treated with apatinib+irinotecan,and the study group was treated with Yangyin Yiwei Jianpi formula on the basis of the control group.The clinical efficacy,quality of life[Karnofsky performance status(KPS)score],traditional Chinese medicine(TCM)syndrome score,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)]and incidence of adverse reactions were compared between the two groups.Result The disease control rate of the study group was higher than that of the control group,and the total incidence of adverse reactions was lower than that of the control group,the differences were statistically significant(P<0.05).After treatment,the KPS score in study group was significantly higher than that in control group,and the difference was statistically significant(P<0.01).After treatment,the scores of TCM syndroms in both groups were lower than those before treatment,and the scores of TCM syndroms in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the CA125 and CEA levels in both groups were lower than those before treatment,and the CA125 and CEA levels in study group were lower than those in control group,the differences were statistically significant(P<0.05).Conclusion Yangyin Yiwei Jianpi formula combined with apatinib and irinotecan can significantly improve the clinical efficacy,TCM syndromes and quality of life of patients with advanced gastric cancer,reduce the levels of tumor markers,and has certain safety.

关 键 词：晚期胃癌 养阴益胃健脾方 阿帕替尼 伊立替康 

分 类 号：R735.2[医药卫生—肿瘤]